Introduction {#Sec1}
============

A real-time reverse transcription--polymerase chain reaction (RT-PCR) test is the gold standard for COVID-19 infection diagnosis. However, sample quality may limit its accuracy. In addition, the RT-PCR test requires a relatively long time. Several studies have compared the consistency between RT-PCR and CT findings \[[@CR1]--[@CR5]\]. In the present study, we aimed to systematically analyze RT-PCR, CT, and the clinical outcome of COVID-19 infection from January 26 to February 4, 2020, to determine whether chest CT was a discriminant for the clinical outcome.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

This retrospective study was approved by the Institutional Review Board of Hainan General Hospital and written informed consent was gained from each patient.

From January 21, 2020, until February 4, 2020, 36 patients with confirmed COVID-19 infection were admitted to our hospitals. Among them, two patients were excluded because chest CT was missing due to the very severe condition of the patient. Thus, 34 patients with chest CT performed in our hospital (NeuViz 128 CT, Neusoft) were included in this study. Chest CT settings were as follows: 120 kV; automatic tube current, 300--496 mA; iterative reconstruction slice thickness, 5 mm.

Four patients did not have a second CT scan. In the other 30 patients, a total of 112 chest CT scans were performed and each patient underwent an average of 4 ± 1 CT scans at a mean interval of 3 ± 1 days. The mean interval between the first and second CT scans was 3 ± 2 days.

CT review {#Sec4}
---------

CT images were analyzed by two trained radiologists with 14 years and 8 years of experience (F.C. and H.J.C., respectively). They reviewed the images independently. If there was a disagreement, a third trained radiologist (Y.C.) adjudicated the final decision.

CT scans were evaluated for the following features: (1) lesion number; (2) lesion distribution; (3) initial location of the lesions; (4) lobe involvement; (5) presence; and (6) lesion patterns, including pure ground-glass opacity (GGO) \[[@CR6]\], GGO with interlobular septal thickening or reticulation, or intralobular networks in GGO, and GGO with consolidation or cavitation; and (7) other abnormalities including pleural effusion, lymphadenopathy (defined as a lymph node \> 1 cm in short-axis diameter), pleural thickening, and pericardial effusion.

A follow-up study was performed in these patients. During follow-up, a semi-quantitative scoring standard was used to quantitatively assess the pulmonary involvement of all lesions according to the area involved \[[@CR7]\]. Five lobes of the lung were assessed based on these criteria: 0, no involvement; 1, \< 5% involvement; 2, 5--25% involvement; 3, 26--49% involvement; 4, 50--75% involvement; 5, \> 75% involvement. The total CT score consisted of the sum of all five lobe scores and ranged from 0 (no involvement) to 25 (maximum involvement). The lesion number, lesion location, initial location of lesions, number of lobes involved, lesion patterns, and scores were compared between discharged patients and ICU patients.

Statistical analysis {#Sec5}
--------------------

Continuous variables are shown as mean ± standard deviation; categorical variables are demonstrated as a percentage (%). Statistical analyses were performed using SPSS software version 21 (SPSS Inc.).

Results {#Sec6}
=======

Clinical manifestations {#Sec7}
-----------------------

The final cohort consisted of 34 patients. The average time interval between the onset of symptoms and admission was 6.3 ± 5.6 days. The average age was 54.5 years (Table [1](#Tab1){ref-type="table"}). There were 23 (62%) men. All patients had an exposure history. The most common symptoms at the onset of illness were fever (29 \[85%\] of 34 patients) and cough (27 \[79%\]) (Table [1](#Tab1){ref-type="table"}). On admission, most patients had a normal (24 \[71%\] patients) or decreased (9 \[26%\] patients) white blood cell count. Twenty-three \[68%\] patients showed lymphopenia (lymphocyte count \< 1.0 × 10^9^/L; Table [1](#Tab1){ref-type="table"}), and 27 (79%) patients presented with decreased eosinophil count. Most (25/33 available data \[76%\]) patients had increased C-reactive protein levels on admission (Table [1](#Tab1){ref-type="table"}).Table 1Demographics and baseline characteristics of patients infected with COVID-19Gender  Female13 (38%)  Male21 (62%)Age (years) (28--73)54.5 ± 11.8Exposure history100%Clinical symptoms  Fever29 (85%)  Cough27 (79%)  Fatigue17 (50%)  Nasal congestion2 (6%)  Rhinorrhea1 (3%)  Sneezing0 (0%)  Sputum production10 (29%)  Hemoptysis1 (3%)  Sore throat7 (19%)  Pleura pain0 (0%)  Diarrhea1 (3%)  Chest tightness8 (24%)Biochemical results  White blood cell count (normal range, 3.5--9.5 × 10^9^/L)24 normal (71%), 9 (26%) decreased, 1 (3%) increased  Lymphocyte percentage (normal range, 20--50%)23 normal (68%), 11 (32%) decreased, 0 increased  Neutrophil count (normal range, 1.8--6.3 × 10^9^/L)27 (79%) normal, 5 (15%) decreased, 2 (6%) increased  Lymphocyte count (normal range, 1.1--3.2 × 10^9^/L)10 (29%) normal, 23 (68%) decreased, 1 (3%) increased  Monocyte count (normal range, 0.1--0.6 × 10^9^/L)30 (88%) normal, 0 decreased, 4 (12%) increased  Eosinophil count (normal range, 0.02--0.52 × 10^9^/L)7 (21%) normal, 27 (79%) decreased, 0 increased  Basophil count (normal range, 0--0.06 × 10^9^/L)33 (97%) normal, 0 decreased, 1 (3%) increasedRed blood cell count; male (normal range, 4.3--5.8 × 10^12^/L); female (normal range, 3.8--5.1 × 10^12^/L)28 (82%) normal, 4 (12%) decreased, 2 (6%) increased  Hemoglobin; male (normal range, 130--175 g/L); female (normal range, 115--150 g/L)29 (85%) normal, 5 (15%) decreased, 0 increased  Hematocrit; male (normal range, 0.4--0.5); female (normal range, 0.35--0.45)27 (79%) normal, 6 (18%) decreased, 1 (3%) increased  Mean corpuscular volume (normal range, 82--100 fL)32 (94%) normal, 2 (6%) decreased, 0 increased  Mean corpuscular hemoglobin (normal range, 27--34 pg)32 (94%) normal, 2 (6%) decreased, 0 increased  Mean corpuscular hemoglobin concentration (MCHC) (normal range, 316--354 g/L)32 (94%) normal, 2 (6%) decreased, 0 increased  Red blood cell volume distribution width RDW-CV (normal range, ≤ 15%)33 (97%) normal, no decreased, 1 (3%) increased  Serum retinol-binding (normal range, 25--70 mg/L)12 (43%) normal, 16 (57%) decreased, 0 increased  C-reactive protein (normal range, 0.068--8.2 mg/L)8 (24%) normal, 0 decreased, 25 (76%) increased

Chest CT scan revealed the typical abnormalities of COVID-19 pneumonia in 32/34 cases, on admission. The average delay from first symptom onset to CT was 6.4 ± 6.5 days. Among them, 10 (29%) had negative results at the initial RT-PCR. These ten patients all presented with typical positive findings on CT (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1A 62-year-old man with a history of exposure, presenting with fever, cough, expectorating white phlegm, nausea, and vomiting. **a**--**c** Axial unenhanced chest CT revealed multiple confluent and patchy ground-glass and consolidative pulmonary opacities in the subpleural area bilaterally upon hospital admission on January 29, 2020. The patient underwent a swab test, which was negative for COVID-19 according to a real-time reverse transcription--polymerase chain reaction (RT-PCR) assay on January 30, 2020. The patient underwent a second swab RT-PCR test on January 31, 2020, and the COVID-19 infection was finally confirmed

Six (18%) patients had a single lesion on the first CT scan, two (6%) had double lesions, and most (26, 76%) patients had multiple lesions. The patients with lesions showed a mainly subpleural area (*N* = 24) distribution or a distribution of both subpleural and centro-parenchymal lesions (*N* = 10). Among the 26 patients with multiple lesions, 4 (12%) had two lobes involved, 1 (2%) had three lobes involved, 6 (18%) had four lobes affected, and 17 had five lobes affected (50%).

The lower lobes were mostly involved (23, 68%, Table [2](#Tab2){ref-type="table"}), 5 (15%) patients having the upper lobe as the primary lesion location, while 6 (18%) patients with lesions scattered. No one showed lung cavitation or lymphadenopathy. One (3%) patient had small amounts of pleural effusion. Fourteen (41%) patients showed pleural thickening. Three (9%) patients showed mild pericardial effusion.Table 2Manifestations of first CT in 34 patientsDetails of imaging examination  Days from first symptom onset to first CT scan6.4 ± 6.5 daysNucleic acid test  Negative in the first RT-PCR10 (31%)  Positive in the first RT-PCR24 (69%)CT imaging stages on admission  Early stage15 (44%)  Progressive stage19 (56%)  Absorption period0Lesion number  Single6 (18%)  Double2 (6%)  Multiple26 (76%)Lesion distribution  Subpleural24 (71%)  Centro-parenchymal0  Both subpleural and centro-parenchymal10 (29%)Primary location of lesions  Upper lobe5 (15%)  Middle lobe0 (0%)  Lower lobe23 (68%)  Scattered distribution6 (17%) (ICU, 3; no ICU, 3)Number of lobes involved  00  16 (18%)  24 (12%)  31 (3%)  46 (18%)  517 (50%)Lesion patterns  Pure ground-glass opacity22 (65%)  GGO with reticular and/or interlobular septal thickening9 (27%)  GGO with consolidation3 (8%)  Cavitation0Other findings  Pleural effusion1 (3%)  Lymphadenectasis0  Pleural thickening14 (4%)  Pericardial effusion3 (9%)

At early stage (0--4 days after first symptom onset), subpleural GGO was the main feature (Figs. [2a](#Fig2){ref-type="fig"} and [3a](#Fig3){ref-type="fig"}). Later (5--13 days after first symptom onset), various imaging features including diffuse GGO and consolidation coexisted (Fig. [2b--d](#Fig2){ref-type="fig"}), with lesion spread to multiple lobes. At the absorption stage (≥ 14 days after first symptom onset), lesions gradually absorbed.Fig. 2A 64-year-old woman, who was a local resident of Wuhan, presented with fever on January 16. Axial unenhanced chest CT revealed patchy ground-glass opacity in the lower lobe of the right lung on January 17 (**a**). Follow-up CT revealed the infection had progressed and the lesions had extended to a bilateral multilobe distribution with consolidation (**b**). **c**, **d** A 73-year-old man presented with cough 8 days before presentation at the hospital. The CT images on admission showed bilateral, multiple lobular and subsegmental areas of GGO with subsegmental areas of consolidation, indicating the disease was severeFig. 3A 50-year-old woman with a history of exposure presented with cough and white phlegm for 4 days, accompanied by headache, muscle aches, and no fever. Axial unenhanced CT scan showed small patchy ground-glass lesions in the left lung and the inferior lobe of the right lung upon hospital admission on January 24, 2020 (**a**). The patient was confirmed with COVID-19 infection on January 26, 2020. The lesions showed progression on January 27, 2020 (**b**). The lesions on a chest CT scan were smaller by January 30, 2020 (**c**). The lesions were absorbed then before February 22, 2020 (**d**). This patient was discharged 4 days later

Prognosis {#Sec8}
---------

Among the 30 patients with available follow-up on CT, 8 showed apparent absorption during follow-up (Table [3](#Tab3){ref-type="table"}, Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}) and were discharged from the hospital. Six patients are still receiving treatment in the intensive care unit, and 28 are still receiving treatment in general wards. Eighty percent of the ICU patients were in the progressive stage of the disease. On the contrary, 75% of the discharged patients were in the early stage of the disease. Four (80%) ICU patients had multiple lesions and the distribution of the lesions involved both the subpleural area and parenchyma (Figs. [2c, d](#Fig2){ref-type="fig"} and [5](#Fig5){ref-type="fig"}), while only 2 (25%) of the discharged patients had both subpleural involvement and centro-parenchymal involvement. Three (60%) ICU patients had scattered lesions, with the primary location of lesions in discharged patients primarily in the lower lobe. Three (60%) ICU patients and 2 (25%) discharged patients had 5 lobes involved, respectively. Three (60%) ICU patients and 3 (37.5%) discharged patients had GGO with reticular and/or interlobular septal thickening/consolidation, respectively. ICU patients had significantly higher scores in the right upper lobe, right middle lobe, and right lower lobe and a higher total score.Table 3CT patterns between ICU and discharged patients on initial CT scanCT patternsICU (5)Discharged (8)Stage  Early stage1 (20%)6 (75%)  Progressive stage4 (80%)2 (25%)  Absorption period00Lesion number  Single1 (20%)1 (12.5%)  Double01 (12.5%)  Multiple4 (80%)6 (75%)Lesion distribution  Subpleural1 (20%)6 (75%)  Centro-parenchymal00  Both subpleural and centro-parenchymal4 (80%)2 (25%)Initial location of lesions  Upper lobe1 (20%)2 (25%)  Middle lobe00  Lower lobe1 (20%)5 (62.5%)  Scattered distribution3 (60%)1 (12.5%)Number of lobes involved  101 (12.5%)  21 (20%)2 (25%)  301 (12.5%)  41 (20%)2 (25%)  53 (60%)2 (25%)Lesion patterns  Pure ground-glass opacity2 (40%)5 (62.5%)  GGO with reticular and/or interlobular septal thickening1 (20%)2 (25%)  GGO with consolidation2 (40%)1 (12.5%)  Cavitation00CT score of every lobe  Right upper lobe1 ± 13 ± 1\*  Right middle lobe1 ± 13 ± 2\*  Right lower lobe1 ± 14 ± 2\*  Left upper lobe1 ± 13 ± 2  Left lower lobe1 ± 13 ± 2  Total score5 ± 315 ± 8\*Quantitative data were expressed as mean ± standard deviation (minimum--maximum). \*Mann-Whitney *U* test showed statistical difference in the right upper lobe, right middle lobe, right lower lobe, and total score between the discharged patients and ICU patientsFig. 4A 55-year-old man, who was a local resident of Wuhan, presented with cough and fever. Fever was accompanied by dizziness, headache, chest tightness, shortness of breath, and diarrhea. Axial unenhanced chest CT showed multiple small patchy ground-glass lesions bilaterally upon hospital admission on January 26, 2020 (**a**). After treatment (**b**, **c**), the lesions on chest CT showed a gradual absorption on January 28, 2020, and February 1, 2020. This patient was discharged 5 days later without clinical symptomsFig. 5A 45-year-old man, who was a local resident of Wuhan and who had a history of exposure, presented with fever, cough, expectorating yellow phlegm, stuffy nose, runny nose, headache, and obvious muscle aches. CT scan revealed multiple sparse patchy ground-glass lesions in the subpleural area and parenchyma bilaterally upon hospital admission on January 21, 2020. The patient was admitted into an intensive care unit. CT revealed obvious progression of the disease on January 25, 2020

Discussion {#Sec9}
==========

Our study demonstrates that chest CT can play a crucial role in early diagnosis of COVID-19, especially in patients with a negative RT-PCR. The present study showed that all 10 patients with a negative first RT-PCR displayed typical CT manifestations at their first CT examination.

Although the specificity of the RT-PCR test is high, its accuracy largely depends on the quality of sampling. In addition, the relatively long detection time may not be adaptable to the clinical workflow and medical decision-making during an outbreak. Our study indicated that patients with a positive CT and a negative RT-PCR should be included in isolation treatment, which may be helpful in controlling the source of infection as soon as possible.

The CT imaging features of COVID-19 pneumonia are not really specific when compared with both H1N1 and SARS \[[@CR8], [@CR9]\]. Multifocal, bilateral ground-glass opacities, with a peripheral subpleural distribution, were found in most of our patients, in accordance with previous studies \[[@CR10]--[@CR14]\].

Beyond diagnosis, the imaging characteristics of progressive lesions on CT may help determine the prognosis. The lesions in 8 patients were decreasing in size and they were discharged from the hospital during follow-up. Five were receiving intensive care at the time of the study. Eighty percent of the ICU patients were in the progressive stage of the disease at their initial appearance, while most of the discharged patients were in the early stage at their first CT scan. CT is helpful in monitoring disease progression and evaluating the effectiveness of treatment. In addition, our study found that lesion involvement and distribution may be used as indicators for subsequent outcomes: the discharged patients showed fewer lobes involved and lesions mainly located in the subpleural area and lower lobe, while the ICU patients seemed to have more lobes involved and a scattered distribution of lesions. This is consistent with the results of Huang et al \[[@CR15]\]. Pure GGO may be associated with a better outcome, while more lobe involvement and a scattered distribution should alert clinicians to a worse prognosis.

This study had several limitations that should be mentioned. The sample size was small. In addition, the present results were from 5-mm-thick slices, which may have misdiagnosed some subtle findings, such as tiny pulmonary nodules.

In conclusion, CT imaging is valuable in the early diagnosis of COVID-19 disease, with a special interest in symptomatic patients with a negative RT-PCR, which can efficiently screen for symptomatic COVID-19 patients in a timely manner. CT is also useful for monitoring follow-up. Early CT features may have a prognostic value. Whether a given treatment is beneficial could also be assessed with chest CT.
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